PMID- 32940395
OWN - NLM
STAT- MEDLINE
DCOM- 20210830
LR  - 20220418
IS  - 1365-3164 (Electronic)
IS  - 0959-4493 (Linking)
VI  - 31
IP  - 6
DP  - 2020 Dec
TI  - Shortened immunotherapy dose-escalation saves time, but is it safe? A 
      case-control study comparing the rates of adverse reactions between conventional 
      and fast-escalation subcutaneous immunotherapy protocols during the induction 
      phase.
PG  - 454-e120
LID - 10.1111/vde.12892 [doi]
AB  - BACKGROUND: Allergen immunotherapy (AIT) is the only intervention believed to 
      change the course of atopic diseases. As dogs appear to have fewer severe adverse 
      events (AEs) compared to people receiving AIT, a prolonged dose-escalation 
      induction phase might not be needed. OBJECTIVES: To report the incidence and 
      characteristics of AEs induced by a fast-escalation subcutaneous immunotherapy 
      (f-SCIT) protocol compared to a conventional (c-SCIT) regimen. ANIMALS: One 
      hundred dogs treated with either f- SCIT (Centre 1, 50 dogs) or c-SCIT (Centre 2, 
      50 dogs). METHODS AND MATERIALS: A case-control study retrospectively evaluating 
      AEs during the induction of AIT. We determined the incidence and type of AEs in 
      each SCIT group; we also assessed factors such as self-limitation and the need 
      for AE-associated protocol changes. RESULTS: Twelve of 100 dogs (12%) developed a 
      SCIT-attributable AE during the induction phase, with one dog having a local and 
      11 having systemic reactions (nine Grade I, two Grade II, none of grades III or 
      IV). Dogs treated with the f-SCIT had a significantly higher rate of AEs (11 of 
      50; 22%) compared to those receiving the c-SCIT (one of 50; 2%). Most of the AEs 
      (10 of 11; 91%) in the f-SCIT group were mild and self-limiting. CONCLUSIONS AND 
      CLINICAL IMPORTANCE: The induction phase of f-SCIT is simpler, and the 
      maintenance phase is reached faster than that of the c-SCIT. Despite its higher 
      rate of AEs than with the c-SCIT regimen, the majority of f-SCIT-associated AEs 
      were mild and self-limiting. Whether or not this f-SCIT protocol leads to a 
      faster time-to-efficacy needs to be determined.
CI  - (c) 2020 ESVD and ACVD.
FAU - Herrmann, Ina
AU  - Herrmann I
AUID- ORCID: 0000-0003-2772-9144
AD  - Department of Clinical Sciences, College of Veterinary Medicine, NC State 
      University, 1060 William Moore Drive, Raleigh, NC, 27607, USA.
FAU - Loft, Klaus E
AU  - Loft KE
AD  - MSPCA Angell Memorial Hospital, 350 South Huntington Avenue, Boston, MA, 02130, 
      USA.
FAU - Olivry, Thierry
AU  - Olivry T
AUID- ORCID: 0000-0003-1399-0034
AD  - Department of Clinical Sciences, College of Veterinary Medicine, NC State 
      University, 1060 William Moore Drive, Raleigh, NC, 27607, USA.
LA  - eng
PT  - Journal Article
DEP - 20200917
PL  - England
TA  - Vet Dermatol
JT  - Veterinary dermatology
JID - 9426187
RN  - 0 (Allergens)
SB  - IM
MH  - *Allergens
MH  - Animals
MH  - Case-Control Studies
MH  - *Desensitization, Immunologic/veterinary
MH  - Dogs
MH  - Injections, Subcutaneous/veterinary
MH  - Retrospective Studies
EDAT- 2020/09/18 06:00
MHDA- 2021/08/31 06:00
CRDT- 2020/09/17 08:49
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/08/31 06:00 [medline]
PHST- 2020/09/17 08:49 [entrez]
AID - 10.1111/vde.12892 [doi]
PST - ppublish
SO  - Vet Dermatol. 2020 Dec;31(6):454-e120. doi: 10.1111/vde.12892. Epub 2020 Sep 17.